Compare ACDC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | 2280 | 423 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2021 | 2015 |
| Metric | ACDC | COLL |
|---|---|---|
| Price | $7.84 | $33.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.50 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 1.3M | 399.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $1,941,800,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | ★ N/A | $83.70 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $3.08 | $28.34 |
| 52 Week High | $10.70 | $50.79 |
| Indicator | ACDC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 44.81 |
| Support Level | $3.48 | $31.56 |
| Resistance Level | N/A | $36.22 |
| Average True Range (ATR) | 0.44 | 1.70 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 82.49 | 8.20 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.